AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 75(4), 2006, pp. 637-639
Copyright © 2006 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RAMHARTER, M.
Right arrow Articles by KREMSNER, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RAMHARTER, M.
Right arrow Articles by KREMSNER, P. G.
Related Collections
Right arrow Malaria

SHORT REPORT


IN VITRO ACTIVITY OF ARTEMISONE COMPARED WITH ARTESUNATE AGAINST PLASMODIUM FALCIPARUM

MICHAEL RAMHARTER*, DOMINIK BURKHARDT, JOHANNES NEMETH, AYOLA A. ADEGNIKA, AND PETER G. KREMSNER
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon; Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Austria; Department of Parasitology, Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany

 

ABSTRACT

Artemisinins show the potential for neurotoxicity in preclinical studies. Artemisone is a leading candidate of second-generation semi-synthetic artemisinin derivatives for antimalarial therapy devoid of neurotoxicity. Artemisone showed 3–5-fold higher in vitro activity (50% effective concentration (EC50) = 0.14 nmol/L, EC90 = 2.55 nmol/L) than artesunate against fresh Plasmodium falciparum isolates from Gabon and a high-activity correlation indicates a shared drug target.

Received April 18, 2006. Accepted for publication June 6, 2006.

Acknowledgments: We are grateful to the children and their parents for participating in this study. We also thank Bayer Healthcare for providing artemisone.

* Address correspondence to Michael Ramharter, Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Austria. E-mail: michael.ramharter{at}meduniwien.ac.at

Authors’ addresses: Michael Ramharter and Johannes Nemeth, Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Ga-bon and Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Austria. Dominik Burkhardt, Ayola A. Adegnika, and Peter G. Kremsner, Department of Parasitology, Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany, and Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
N. Obaldia III, B. M. Kotecka, M. D. Edstein, R. K. Haynes, B. Fugmann, D. E. Kyle, and K. H. Rieckmann
Evaluation of Artemisone Combinations in Aotus Monkeys Infected with Plasmodium falciparum
Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3592 - 3594.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Tropical Medicine and Hygiene.